Recent 8-K filings for SNOA
Highest-materiality recent filing
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
- Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
- Term includes two optional one-year renewals upon mutual written agreement.
-
Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit
Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
-
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
-
Sonoma Pharmaceuticals appoints Vanessa Jacoby to board; Birnbaum retires as director
Dr. Jay Birnbaum retired from board Jan 28, 2026; will serve as consultant for one year, receiving 5,000 RSUs per quarter.
-
Filing includes an updated investor presentation as of January 2026, furnished as Exhibit 99.1.
-
Sonoma Pharmaceuticals grants annual equity to executives and directors
Non-employee directors each received 10,000 options at $3.68, vesting in 3 equal annual tranches.
-
Sonoma Pharma terminates EVP/COO Bruce Thornton for cause, effective Oct 18
Bruce Thornton terminated as EVP and Chief Operating Officer on October 18, 2025.
-
CEO Amy Trombly amends employment agreement; COO Bruce Thornton retires, position eliminated
CEO Amy Trombly's base salary set at $475,000 per annum; target annual bonus of 50% of base salary.
-
Sonoma Pharmaceuticals files updated investor presentation; no material new details disclosed
Furnished updated investor presentation dated September 29, 2025, under Item 8.01.
-
Sonoma Pharma enters $2.07M ATM stock offering with Ladenburg Thalmann
At Market Issuance Sales Agreement with Ladenburg Thalmann for up to $2,070,463 of common stock.
-
Sonoma Pharmaceuticals shareholders elect director, approve executive compensation and auditor
Dr. Jay Birnbaum elected Class II director with 123,034 votes for, 19,478 withheld.
-
Sonoma Pharmaceuticals files updated investor presentation; no specific new data in excerpt
Company filed an updated investor presentation as of April 28, 2025, under Item 8.01.
-
Sonoma Pharmaceuticals posts updated investor presentation with no material new information
Filed updated investor presentation as of April 7, 2025, under Item 8.01.
-
Sonoma expands Microcyn distribution deal with WellSpring to include additional products
Amendment No. 1 dated March 21, 2025 adds new Microcyn-based products to existing Master Supply Agreement.
-
Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products
Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.
-
Sonoma Pharma grants 7,500 options to directors and 10,000 RSUs to each top executive
Non-employee directors each received 7,500 options at $2.68, vesting over three years.
-
Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma
EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.
-
Sonoma expands Medline distribution to Canada and OTC retail in US and Canada
Amendment No. 1 to Distribution Agreement with Medline dated Oct 17, 2024 adds Canada and OTC wound care sales to retailers.
-
Sonoma Pharmaceuticals files prospectus supplement for existing ATM equity offering with Maxim Group
Company entered Equity Distribution Agreement with Maxim Group on Dec 15, 2023, amended March 8, 2024.
-
Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
-
Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering
Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.
-
Sonoma Pharmaceuticals enters 5-year distribution agreement with Medline for wound care products
Distribution agreement effective August 19, 2024, covers wound cleansers and other products in the United States.
-
Sonoma Pharmaceuticals files prospectus supplement for ATM equity facility
Filed a prospectus supplement on June 27, 2024 for at-the-market offering of common stock through Maxim Group LLC.
-
Presentation covers stabilized hypochlorous acid products for wound, eye, oral, nasal, and dermatological care.
-
Sonoma Pharmaceuticals updates investor presentation; no material changes
HOCl product portfolio covers wound, eye, oral, nasal, dermatology, podiatry, and animal health
-
Nasdaq grants Sonoma Pharmaceuticals 180-day extension to meet $1.00 bid price rule
Company received until September 16, 2024 to regain compliance with Nasdaq minimum $1.00 closing bid price rule.
-
Sonoma Pharmaceuticals increases ATM offering capacity by $785,679
Amendment No. 1 to Dec 2023 Equity Distribution Agreement with Maxim Group LLC allows sale of up to $785,679 in additional common shares.
-
Sonoma provides January 2024 investor presentation; no material new financial data
Presentation reiterates stabilized HOCl platform for dermatology, wound, eye, nasal, oral, animal health.
-
Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products
Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.
-
Sonoma Pharmaceuticals grants 180,000 stock options to executive officers at $0.18 per share
CEO Amy Trombly, interim CFO Jerry Dvonch, and COO Bruce Thornton each received 60,000 options.
-
ATM facility allows Sonoma to sell up to $392,077 of common stock through Maxim Group.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.35 · Most common event other_material